Sign Out
Hypersensitivity to any of the excipients.
Patients with FEV1 < 70% of predicted value (after adequate pharmacological treatment) at initiation of treatment.
Patients who have experienced a severe asthma exacerbation within the last 3 months.
In patients with asthma and experiencing an acute respiratory tract infection, initiation of Dermatophagoides pteronyssinus extract and Dermatophagoides farinae extract (Acarizax) treatment should be postponed until the infection has resolved.
Patients with active or poorly controlled autoimmune diseases, immune defects, immunodeficiencies, immunosuppression or malignant neoplastic diseases with current disease relevance.
Patients with acute severe oral inflammation or oral wounds (see Precautions).
